Canine lymphoma subtypes
| WHO subtype . | DLBCL . | MZL . | FL . | PTCL . | T-LBL . | TZL . |
|---|---|---|---|---|---|---|
| Cell lineage | B | B; frequent aberrant CD5+ in splenic MZL | B | T; most frequently CD4+ | T; most frequently CD4+ CD8+ or CD4− CD8− | T; usually CD45− and occasional aberrant CD21+ |
| Grade | High | Splenic variant considered low grade (indolent); however, nodal MZL exhibits high-grade behavior | Low (indolent) | High | High | Low (indolent) |
| Changes to nodal architecture | Diffuse | Nodular; surrounding germinal center remnants | Nodular; follicular | Diffuse | Diffuse | Nodular; paracortical expansion |
| Examples of frequently mutated genes and dysregulated pathways | NF-κB, PI3K-AKT, and JAK-STAT | MYC documented in nodal MZL | BCL-2 | PTEN, MTOR | Not well classified | SPAM1, HYAL4, and HYALP1 |
| Common first-line treatments | CHOP | Splenectomy can be curative for splenic MZL; multiagent chemotherapy (CHOP) considered for nodal MZL | Active surveillance; chlorambucil and prednisone considered for progressive disease | CHOP | CHOP | Active surveillance; chlorambucil and prednisone considered for progressive disease |
| WHO subtype . | DLBCL . | MZL . | FL . | PTCL . | T-LBL . | TZL . |
|---|---|---|---|---|---|---|
| Cell lineage | B | B; frequent aberrant CD5+ in splenic MZL | B | T; most frequently CD4+ | T; most frequently CD4+ CD8+ or CD4− CD8− | T; usually CD45− and occasional aberrant CD21+ |
| Grade | High | Splenic variant considered low grade (indolent); however, nodal MZL exhibits high-grade behavior | Low (indolent) | High | High | Low (indolent) |
| Changes to nodal architecture | Diffuse | Nodular; surrounding germinal center remnants | Nodular; follicular | Diffuse | Diffuse | Nodular; paracortical expansion |
| Examples of frequently mutated genes and dysregulated pathways | NF-κB, PI3K-AKT, and JAK-STAT | MYC documented in nodal MZL | BCL-2 | PTEN, MTOR | Not well classified | SPAM1, HYAL4, and HYALP1 |
| Common first-line treatments | CHOP | Splenectomy can be curative for splenic MZL; multiagent chemotherapy (CHOP) considered for nodal MZL | Active surveillance; chlorambucil and prednisone considered for progressive disease | CHOP | CHOP | Active surveillance; chlorambucil and prednisone considered for progressive disease |
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone.